Clinical Trial

Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus Desloratadine

Study acronym: DESCUBRA
Completed Phase 3
View on ClinicalTrials.gov →
Summary
Phase IIIb , longitudinal, multicenter, randomized, double-blind, to evaluate efficacy and safety of the fixed-dose combination of Desloratadine 5 mg / Betamethasone 0.25 mg versus Desloratadine 5 mg monotherapy as treatment for symptoms associated with allergic rhinitis.
Protocol Amendment History 4 changes
critical Trial completed 2026-07-24
critical Primary endpoint(s) modified 2026-07-24
notable Primary completion pushed: 2025-05-11 -> 2025-10-15 2026-07-24
minor Completion pushed: 2025-06-11 -> 2025-11-15 2026-07-24
Trial Details
NCT Number NCT06916884
Lead Sponsor Laboratorios Silanes S.A. de C.V.
Conditions Allergic Rhinitis
Enrollment 70 participants
Start Date 2024-11-11
Primary Completion 2025-10-15 (estimated)
Study Completion 2025-11-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-23